| centanafadine SR (EB-1020) / Otsuka |
NCT04398225: A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine in Pediatric Subjects With Attention-deficit/Hyperactivity Disorder |
|
|
| Completed | 1b | 32 | US | Centanafadine | Otsuka Pharmaceutical Development & Commercialization, Inc. | Attention Deficit Hyperactivity Disorder | 04/21 | 04/21 | | |
NCT04786730: A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder |
|
|
| Completed | 1b | 50 | US | Centanafadine | Otsuka Pharmaceutical Development & Commercialization, Inc. | Attention-deficit Hyperactivity Disorder | 04/23 | 04/23 | | |
NCT01744808: A Study to Evaluate the Safety, Tolerance, and Pharmacokinetic and Pharmacodynamic Profile Of 1 SR Formulation of EB-1020 |
|
|
| Completed | 1 | 54 | RoW | EB-1020 IR, EB-1020 SR1, EB-1020 SR2, EB-1020 SR3, Placebo | Neurovance, Inc. | Normal, Healthy Volunteers | 02/14 | 02/14 | | |
NCT02144415: A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users |
|
|
| Completed | 1 | 80 | US | EB-1020 400 mg, EB-1020 800 mg, lisdexamfetamine 150 mg, d-amphetamine 40 mg, Placebo | Neurovance, Inc. | Healthy Volunteers, Drug Users | 07/14 | 07/14 | | |
NCT02827513: A Phase 1 Study to Investigate the Safety, Tolerance, Food Effect, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Extended Release Formulations of Centanafadine (CTN) in Young Healthy Subjects |
|
|
| Terminated | 1 | 16 | RoW | CTN SR1, Centanafadine, CTN XR1, CTN XR2, CTN XR3 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Adult Attention-deficit Hyperactivity Disorder (ADHD) | 01/16 | 01/16 | | |
